TITLE

Mycobacterium xenopi Clinical Relevance and Determinants, the Netherlands

AUTHOR(S)
Van Ingen, Jakko; Boeree, Martin J.; De Lange, Wiel C. M.; Hoefsloot, Wouter; Bendien, Saar A.; Magis-Escurra, Cecile; Dekhuijzen, Richard; Van Soolingen, Dick
PUB. DATE
March 2008
SOURCE
Emerging Infectious Diseases;Mar2008, Vol. 14 Issue 3, p385
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In the Netherlands, isolation of Mycobacterium xenopi is infrequent, and its clinical relevance is often uncertain. To determine clinical relevance and determinants, we retrospectively reviewed medical files of all patients in the Netherlands in whom M. xenopi was isolated from January 1999 through March 2005 by using diagnostic criteria for nontuberculous mycobacterial infection published by the American Thoracic Society. We found 49 patients, mostly white men, with an average age of 60 years and pre-existing pulmonary disease; of these patients, 25 (51%) met the diagnostic criteria. Mycobacterial genotype, based on 16S rRNA gene sequencing, was associated with true infection. Most infections were pulmonary, but pleural and spinal infections (spinal in HIV-infected patients) were also noted. Treatment regimens varied in content and duration; some patients were overtreated and some were undertreated.
ACCESSION #
31323712

 

Related Articles

  • Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel. Levy, Isaac; Grisaru-Soen, Galia; Lerner-Geva, Liat; Kerem, Eitan; Blau, Hana; Bentur, Lea; Aviram, Micha; Rivlin, Joseph; Picard, Elie; Lavy, Anita; Yahav, Yakov; Rahav, Galia // Emerging Infectious Diseases;Mar2008, Vol. 14 Issue 3, p378 

    This 2-year cross-sectional evaluation of nontuberculous mycobacterial (NTM) infections involved all Israeli medical centers that treat cystic fibrosis patients. The study comprised 186 patients whose sputum was analyzed for NTM. The prevalence of NTM isolates was 22.6%, and 6.5% and 10.8% of...

  • Viral Decay Rates are Similar in HIV-infected Patients with and without TB Coinfection during Treatment with an Efavirenz-based Regimen. Lartey, Margaret; Sagoe, Kwamena W.; Hongmei Yang; Kenu, Ernest; Xexemeku, Fafa; Oliver-Commey, Joseph; Boima, Vincent; Seshie, Markafui; Sagoe, Augustine; Mingle, Julius A. A.; Flanigan, Timothy P.; Hulin Wu; Kwara, Awewura // Clinical Infectious Diseases;2/15/2011, Vol. 52 Issue 4, p547 

    Viral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were...

  • Progression to Active Tuberculosis, but Not Transmission, Varies by Mycobacterium tuberculosis Lineage in The Gambia. de Jong, Bouke C.; Hill, Philip C.; Aiken, Alex; Awine, Timothy; Antonio, Martin; Adetifa, Ifedayo M.; Jackson-Sillah, Dolly J.; Fox, Annette; DeRiemer, Kathryn; Gagneux, Sebastien; Borgdorff, Martien W.; McAdam, Keith P. W. J.; Corrah, Tumani; Small, Peter M.; Adegbola, Richard A. // Journal of Infectious Diseases;10/1/2008, Vol. 198 Issue 7, p1037 

    Background. There is considerable variability in the outcome of Mycobacterium tuberculosis infection. We hypothesized that Mycobacterium africanum was less likely than M. tuberculosis to transmit and progress to tuberculosis disease. Methods. In a cohort study of patients with tuberculosis and...

  • T-SPOT.TB responses during treatment of pulmonary tuberculosis. Ribeiro, Samantha; Dooley, Kelly; Hackman, Judith; Loredo, Carla; Efron, Anne; Chaisson, Richard E.; Conde, Marcus B.; Boechat, Neio; Dorman, Susan E. // BMC Infectious Diseases;2009, Vol. 9 Issue 1, Special section p1 

    Background: Immune responses to Mycobacterium tuberculosis antigens could serve as surrogate markers of treatment response. Methods: Using the T-SPOT.TB assay and frozen peripheral blood mononuclear cells, we enumerated ESAT-6- and CFP-10-specific IFN-γ-producing T cells over time in...

  • Reinfection with Mycobacterium tuberculosis after Treatment: Canada and the United States. Deresinski, Stan // Clinical Infectious Diseases;4/1/2005, Vol. 40 Issue 7, preceding p915 

    This article focuses on reinfection with mycobacterium tuberculosis after treatment. An accurate estimate of the proportion of cases due to reinfection in Canada and the United States, where the annual incidence of TB is !6 cases per 100,000 population, has previously been lacking. The...

  • Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. Mayanja-kizza, Harriet; Jones-lopez, Edward; Okwera, Alphonse; Wallis, Robert S.; Elmer, Jerrold J.; Muqerwa, Roy D.; Whalen, Christopher C.; Ellner, Jerrold J; Mugerwa, Roy D; Uganda-Case Western Research Collaboration // Journal of Infectious Diseases;3/15/2005, Vol. 191 Issue 6, p856 

    Background. Human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB) respond to effective antituberculous therapy, but their prognosis remains poor. Mounting evidence from clinical studies supports the concept of copathogenesis in which immune activation that is triggered by...

  • Tuberculous tenosynovitis. Sanders, Clayton J.; Schucany, William G. // Baylor University Medical Center Proceedings;Jan2008, Vol. 21 Issue 1, p71 

    The article provides information related to Mycobacterium tuberculosis. Mycobacterium tuberculosis remain the top-10 cause of death worldwide. Tuberculosis is spread primarily by inhalation of infected droplets, resulting in pulmonary disease. Tuberculous tenosynovitis is a rare complication of...

  • Atypical Pneumonia in a Man with Acquired Immunodeficiency Syndrome. Smith, Holly D.; Flenaugh, Eric L. // Clinical Infectious Diseases;8/1/2002, Vol. 35 Issue 3, p334 

    Focuses on patients with endobronchial mycobacteriosis due to Mycobacterium kansasii. Symptoms of Mycobacterium kansasii infection; Treatment; Case of a patient with HIV who developed Mycobacterium kansasii infection.

  • Validity of a self-reported history of a positive tuberculin skin test. A prospective study of drug users. Kunins, Hillary V.; Howard, Andrea A.; Klein, Robert S.; Arnsten, Julia H.; Litwin, Alain H.; Schoenbaum, Ellie E.; Gourevitch, Marc N. // JGIM: Journal of General Internal Medicine;Oct2004, Vol. 19 Issue 10, p1039 

    Objective: To define the prevalence of and factors associated with having a negative purified protein derivative (PPD) among persons who self-report a prior positive PPD and to define the safety of repeat testing in such persons.Design: Observational cohort...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics